Huber H, Grünewald K
Wien Klin Wochenschr. 1978 Dec 22;90(24):861-4.
Indications and results are reviewed with regard to recent data on the effect of DTIC in patients with malignant melanoma, soft tissue sarcomas, Hodgkin's disease, gastrointestinal carcinomas and oat cell cancer of the lung. Whilst this drug induced--mainly partial--remissions in 25% of the patients with melanomas, it is generally used in other malignant conditions in combination with other cytoxic agents. In soft tissue sarcomas adriamycin appeared as the principal additional drug. In patients with Hodgkin's disease resistant to MOPP treatment and requiring additional cytotoxic drugs, combination chemotherapy including DTIC may induce remissions in more than half of these patients. Other schedules were, however, also effective and results in this difficult group of patients are discussed and compared. In gastrointestinal and in oat cell carcinomas cytotoxic protocols including DTIC have shown some effect, perhaps comparable to other combinations usually employed in these conditions.
结合近期有关达卡巴嗪（DTIC）对恶性黑色素瘤、软组织肉瘤、霍奇金病、胃肠道癌和肺燕麦细胞癌患者疗效的数据，对其适应症和结果进行了综述。虽然该药物在25%的黑色素瘤患者中诱导了——主要是部分——缓解，但它通常与其他细胞毒性药物联合用于其他恶性疾病。在软组织肉瘤中，阿霉素是主要的附加药物。在对MOPP治疗耐药且需要额外细胞毒性药物的霍奇金病患者中，包括DTIC的联合化疗可能使超过一半的患者缓解。然而，其他方案也有效，本文讨论并比较了这一困难患者群体的治疗结果。在胃肠道癌和肺燕麦细胞癌中，包括DTIC的细胞毒性方案已显示出一定疗效，可能与这些疾病通常使用的其他联合方案相当。
